Pharmacist Medication Insights: Somapacitan (Sogroya) for Growth Hormone Deficiency

Video

Somapacitan (Sogroya; Novo Nordisk) injection is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

Somapacitan (Sogroya; Novo Nordisk) injection is approved for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

The human growth hormone analogue is administered via subcutaneous injection once weekly.

Somapacitan acts similarly to human growth hormone. After injection, the drug attaches to a protein in the blood called albumin, which allows it remain in the body for longer. This enables weekly administration of Sogroya, which is favorable to the daily dosing of other growth hormone replacement therapies.

Related Videos
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.